Background/Aims Recently, the Korean Association for the Study of the Liver (KASL) introduced a noninvasive test-based approach that uses the fibrosis-4 (FIB-4) index followed by vibration-controlled transient elastography (VCTE) to identify high-risk patients with metabolic-associated steatotic liver disease (MASLD). In this study, the KASL two-step approach was validated by assessing the risk of liver-related event (LRE) development.
Methods We retrospectively analyzed 8,131 patients with MASLD who underwent VCTE between 2012 and 2020. The index date was defined as the date of the VCTE measurement. Using the KASL two-step approach (FIB-4 index and subsequent VCTE), patients were stratified into four groups (low-, intermediate-low-, intermediate-high-, and high-risk groups). Outcomes, including LREs such as decompensation (DCC) or hepatocellular carcinoma (HCC) were evaluated.
Results During the follow-up (median 46.6 months), 86 (1.1%) patients developed LREs (39 [0.5%] with DCC and 47 [0.6%] with HCC). The KASL two-step approach classified 67.6%, 17.7%, 5.7% and 9.0% of patients in the low-, intermediate-low-, intermediate-high-, and high-risk groups, respectively. The cumulative incidences of LREs increased proportionally according to risk stratification (0.07%, 0.10%, 0.29%, and 1.51% at 3 years and 0.35%, 0.26%, 1.94% and 5.46% at 5 years). The overall accuracy in predicting LREs ranged from 67.7–99.8%. The FIB-4 index and subsequent Agile3+, Agile 4, or FibroScan aspartate aminotransferase scores showed similar predictive abilities compared to the KASL approach.
Conclusions The KASL two-step approach is an effective and practical method for risk stratification in patients with MASLD, optimizing patient care through early identification of high-risk individuals.
Citations
Citations to this article as recorded by
Validation of combo ichroma as a reliable concentration-based alternative for AST and ALT measurement in liver disease monitoring Minsoo Kim, Su A Kim, Jeong Min Kim, Hee Young Kim, Ho Yeong Yoon, Sung Won Park, Daegyun Park, Ji Sook Han, Ki Tae Suk Methods.2025; 243: 66. CrossRef
Correspondence to letter to the editor on “Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease: The KASL Pathway Hye Won Lee, Seung Up Kim Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Jihyun An, Young Eun Chon, Gunho Kim, Mi Na Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Miyoung Choi, Dae Won Jun, Seung Up Kim, Ji Won Han, Young-Joo Jin
Clin Mol Hepatol 2024;30(Suppl):S134-S146. Published online August 21, 2024
Background/Aims The assessment of liver fibrosis is crucial for managing autoimmune liver diseases such as primary biliary cholangitis (PBC), autoimmune hepatitis (AIH), and primary sclerosing cholangitis (PSC). However, data on the efficacy of noninvasive tests for these diseases are limited. This meta-analysis evaluated the diagnostic accuracy of vibration-controlled transient elastography (VCTE) for staging fibrosis in patients with autoimmune liver disease.
Methods Searches were conducted in PubMed, Embase, CINAHL, Web of Science, and Cochrane Library databases to assess the diagnostic accuracy of VCTE against histology as the reference standard in adult patients with autoimmune liver disease. The summary area under the curve (sAUC) and diagnostic odds ratio were calculated for significant fibrosis (SF), advanced fibrosis (AF), and cirrhosis, according to liver biopsy.
Results Fourteen articles were included, comprising 559 PBC patients from six studies, 388 AIH patients from five studies, and 151 PSC patients from three studies. VCTE demonstrated good performance for fibrosis staging in PBC, AIH, and PSC. In PBC, sAUCs of VCTE were 0.87, 0.89, and 0.99 for staging SF, AF, and cirrhosis, respectively. In AIH, the sAUCs were 0.88, 0.88, and 0.92, respectively, while in PSC, they were 0.88, 0.95, and 0.92, respectively. The cutoff values for AF were 7.5–17.9 kPa in PBC, 8.18–12.1 kPa in AIH, and 9.6 kPa in PSC.
Conclusions VCTE shows high diagnostic accuracy for staging liver fibrosis in patients with autoimmune liver diseases. This non-invasive method serves as a valuable tool for the evaluation and monitoring of fibrosis in these lifelong diseases.
Citations
Citations to this article as recorded by
Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details: Editorial on “Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver di Kyung-Ah Kim Clinical and Molecular Hepatology.2025; 31(1): 275. CrossRef
Diagnostic value of serum Golgi protein 73 in liver fibrosis and inflammation in patients with autoimmune hepatitis Yazhen Zhang, Aifang Xu, Yujiao Jin, Jing Gao, Jiahui He Medicine.2025; 104(26): e43064. CrossRef
Targeting endoplasmic reticulum proteostasis in liver fibrosis: From signaling mechanisms to therapeutic opportunities Yawei Kong, Zhengyang Chen, Zhentian Nie, Wei Chen Pharmacological Research.2025; 217: 107823. CrossRef
Diagnostic Performance of SWE and Predictive Models Based on SWE for Post-Hepatectomy Liver Failure: A Systematic Review and Meta-analysis Jiaxu Liang, Fukun Shi, Lan Zhang, Suo Yin, Yong Chen Current Medical Imaging Formerly Current Medical Imaging Reviews.2025;[Epub] CrossRef
Hidden weaknesses and biological insights in machine learning models of fibrosis in autoimmune hepatitis Shiuan-Chih Chen, Chun-Chieh Chen QJM: An International Journal of Medicine.2025;[Epub] CrossRef
Background/aims Opinions differ regarding vibration-controlled transient elastography and magnetic resonance elastography (VCTE/MRE) cut-offs for diagnosing advanced fibrosis (AF) in patients with non-alcoholic fatty liver disease (NAFLD). We investigated the diagnostic performance and optimal cut-off values of VCTE and MRE for diagnosing AF.
Methods Literature databases, including Medline, EMBASE, Cochrane Library, and KoreaMed, were used to identify relevant studies published up to June 13, 2023. We selected studies evaluating VCTE and MRE regarding the degree of liver fibrosis using liver biopsy as the reference. The sensitivity, specificity, and area under receiver operating characteristics curves (AUCs) of the pooled data for VCTE and MRE for each fibrosis stage and optimal cut-offs for AF were investigated.
Results A total of 19,199 patients from 63 studies using VCTE showed diagnostic AUC of 0.83 (95% confidence interval: 0.80–0.86), 0.83 (0.80–0.86), 0.87 (0.84–0.90), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. Similarly, 1,484 patients from 14 studies using MRE showed diagnostic AUC of 0.89 (0.86–0.92), 0.92 (0.89–0.94), 0.89 (0.86–0.92), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. The diagnostic AUC for AF using VCTE was highest at 0.90 with a cut-off of 7.1–7.9 kPa, and that of MRE was highest at 0.94 with a cut-off of 3.62–3.8 kPa.
Conclusions VCTE (7.1–7.9 kPa) and MRE (3.62–3.8 kPa) with the suggested cut-offs showed favorable accuracy for diagnosing AF in patients with NAFLD. This result will serve as a basis for clinical guidelines for non-invasive tests and differential diagnosis of AF.
Citations
Citations to this article as recorded by
Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analy Young Eun Chon, Jung Hwan Yu, Seung Up Kim Clinical and Molecular Hepatology.2025; 31(1): e61. CrossRef
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fib Won Sohn Clinical and Molecular Hepatology.2025; 31(1): 277. CrossRef
Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analys Jung Hwan Yu, Seung Up Kim Clinical and Molecular Hepatology.2025; 31(1): e52. CrossRef
Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver d Yangyue Zhang, Vincent Wai-Sun Wong Clinical and Molecular Hepatology.2025; 31(1): 264. CrossRef
Sustainability of General Population Screening for Steatotic Liver Disease: A Proof-of-Concept Study Laura De Rosa, Gabriele Ricco, Maurizia Rossana Brunetto, Ferruccio Bonino, Francesco Faita Healthcare.2025; 13(7): 759. CrossRef
Therapeutic Efficacy of Silymarin, Vitamin E, and Essential Phospholipid Combination Therapy on Hepatic Steatosis, Fibrosis, and Metabolic Parameters in MASLD Patients: A Prospective Clinical Study Dan-Ionuț Gheonea, Cristina Tocia, Victor-Mihai Sacerdoțianu, Alexandra-Georgiana Bocioagă, Irina-Paula Doica, Nicolae Cătălin Manea, Adina Turcu-Știolică, Carmen-Nicoleta Oancea, Eugen Dumitru International Journal of Molecular Sciences.2025; 26(12): 5427. CrossRef
Deep learning radiomics of elastography for diagnosing compensated advanced chronic liver disease: an international multicenter study Xue Lu, Haoyan Zhang, Hidekatsu Kuroda, Matteo Garcovich, Victor de Ledinghen, Ivica Grgurević, Runze Linghu, Hong Ding, Jiandong Chang, Min Wu, Cheng Feng, Xinping Ren, Changzhu Liu, Tao Song, Fankun Meng, Yao Zhang, Ye Fang, Sumei Ma, Jinfen Wang, Xiaol Visual Computing for Industry, Biomedicine, and Art.2025;[Epub] CrossRef
Liver disease in people with latent autoimmune diabetes in adults (LADA): A cross-sectional study using magnetic resonance elastography Ernesto Maddaloni, Marta Zerunian, Vincenzo Cardinale, Annalisa Zurru, Rocco Amendolara, Daniela Luverà, Renata Risi, Luca D’Onofrio, Benedetta Masci, Francesco Covotta, Damiano Caruso, Domenico Alvaro, Andrea Laghi, Raffaella Buzzetti Diabetes Research and Clinical Practice.2025; 229: 112465. CrossRef
Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang Hepatology Communications.2025;[Epub] CrossRef
Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Wolf in Sheep's Clothing Xixi Fang, Chenhao Xu, Jun Lu, Runzhou Zhuang, Xiao Xu, Xuyong Wei Cell Biochemistry and Function.2025;[Epub] CrossRef
Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva Expert Review of Gastroenterology & Hepatology.2025; : 1. CrossRef
Jung Hwan Yu, Ji Won Han, Young Ju Suh, Young Eun Chon, Hee Yeon Kim, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Dae Won Jun, Han Ah Lee, Mi Na Kim
Clin Mol Hepatol 2024;30(Suppl):S186-S198. Published online August 21, 2024
Backgrounds/Aims This meta-analysis examined whether preoperative vibration-controlled transient elastography (VCTE) can predict postoperative complications and recurrence in patients undergoing hepatic resection for hepatocellular carcinoma (HCC).
Methods A systematic literature search was conducted using Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases. Out of 431 individual studies, thirteen published between 2008 and 2022 were included. Five studies focused on HCC recurrence, while eight examined postoperative complications.
Results The meta-analysis of five studies on HCC recurrence showed that the high-risk group with a high VCTE score had a significantly increased recurrence rate after hepatic resection (hazard ratio 2.14). The cutoff value of VCTE in the high-risk group of HCC recurrence was 7.4–13.4 kPa, the sensitivity was 0.60 (95% confidence interval [CI] 0.47–0.72), and the specificity was 0.60 (95% CI 0.46–0.72). The area under the receiver operating characteristic curve (AUC) of the liver stiffness measured by VCTE to predict the HCC recurrence was 0.63 (95% CI 0.59–0.67). The meta-analysis on the postoperative complications revealed a significantly increased risk of postoperative complications in the high-risk group (12–25.6 kPa) with a high VCTE value (odds ratio [OR], 8.32). The AUC of the liver stiffness measured by VCTE to predict the postoperative complications was 0.87 (95% CI 0.84–0.90), the sensitivity was 0.76 (95% CI 0.55–0.89) and the specificity was 0.85 (95% CI 0.73–0.92).
Conclusions This meta-analysis suggests that preoperative VCTE in patients undergoing hepatic resection for HCC is useful in identifying individuals at a high risk of postoperative complications and HCC recurrence.
Citations
Citations to this article as recorded by
Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease Jung Hwan Yu The Korean Journal of Medicine.2024; 99(5): 232. CrossRef
Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2024;30(Suppl):S5-S105. Published online August 19, 2024
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis” Hee Yeon Kim, Miyoung Choi, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e48. CrossRef
Non-Invasive Liver Fibrosis Test Using Shear Wave Elastography Ji Won Han The Korean Journal of Medicine.2025; 100(1): 26. CrossRef
Influence of Sex in the Development of Liver Diseases Jie-Wen Zhang, Nan Zhang, Yi Lyu, Xu-Feng Zhang Seminars in Liver Disease.2025; 45(01): 015. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
Noninvasive identification of metabolic dysfunction–associated steatohepatitis (INFORM MASH): a retrospective cohort and disease modeling study G. Craig Wood, Anthony Hoovler, Rakesh Luthra, Christopher D. Still, Hamzah Shariff, Matthew Still, Jonathan Hayes, Peter Benotti, Chioma Uzoigwe Expert Review of Gastroenterology & Hepatology.2025; 19(4): 427. CrossRef
Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liv Ji Won Han, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(2): e152. CrossRef
The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang BMC Gastroenterology.2025;[Epub] CrossRef
Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C Beom Kyung Kim Journal of Gastroenterology and Hepatology.2025; 40(8): 1855. CrossRef
Novel Insights into Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C Patients Guanlan Liu, Li Liu, Xing Yang, Qihao Wang, Mingqin Qian Journal of Clinical and Experimental Hepatology.2025; 15(6): 102610. CrossRef
A Case Report of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Improved Cardiometabolic Risk Factors Following Treatment with Saenggangunbi-tang Eun Kyung Lee, Min Jeong Park, Youngchul Kim, Jang-Hoon Lee The Journal of Internal Korean Medicine.2025; 46(2): 303. CrossRef
Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Clinical and Molecular Hepatology.2025; 31(3): 1018. CrossRef
Performance of APRI and FIB-4 Scores Compared to FibroScan: A Cross-Sectional Study in a Black Sub-Saharan African Population Jean-Bonny Nsumbu, Jean-Robert Makulo, Trésor Mutombo Tshiswaka, Christian Kisoka Lusunsi, Charles Nlombi Mbendi Hepatic Medicine: Evidence and Research.2025; Volume 17: 27. CrossRef
Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis” Haiyu Wang, Jinjun Chen Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis Toshikazu Kohira, Satoshi Oeda, Erina Eto, Yoshihito Kubotsu, Misa Norita, Kaori Inoue, Nagisa Hara, Shotaro Noge, Kenichi Tanaka, Shigenobu Yoshimura, Noriko Oza, Keizo Anzai, Yuichiro Eguchi, Cheng Han Ng, Daniel Q. Huang, Mark D. Muthiah, Atsushi Kawag Scientific Reports.2025;[Epub] CrossRef
Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim Medicina.2025; 61(9): 1601. CrossRef
Comment on ‘Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank’ by T. S. Lim et al.—Authors' Reply Tae Seop Lim, Sujin Kwon, Sung A Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis Brian Lee, Ussama Ghumman, Lisa D. Pedicone, Andres Gomez Aldana, Eric Lawitz Clinical and Molecular Hepatology.2025; 31(4): 1167. CrossRef
Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li European Journal of Medical Research.2025;[Epub] CrossRef
Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva Expert Review of Gastroenterology & Hepatology.2025; : 1. CrossRef
Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-male-albumin-bilirubin-platelet (aMAP) and Liver Stiffness Assessed by Vibration-controlled Transient Elastography Hye Yeon Chon, Hyung Joon Yim, Seok-Jae Heo, Su Jong Yu, Ja Kyung Kim, Sang Hoon Ahn, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip, Sang Gyune Kim, Yeon Seok Seo, Seung Up Kim Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease Jung Hwan Yu The Korean Journal of Medicine.2024; 99(5): 232. CrossRef
Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography Mi Na Kim The Korean Journal of Gastroenterology.2024; 84(5): 201. CrossRef
Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B Ye Ji Jun, Minjong Lee, Ho Soo Chun, Tae Hun Kim The Korean Journal of Gastroenterology.2024; 84(5): 206. CrossRef
Serological Markers to Assess Liver Fibrosis and Their Roles Beom Kyung Kim The Korean Journal of Gastroenterology.2024; 84(5): 195. CrossRef
Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography Han Ah Lee Clinical Ultrasound.2024; 9(2): 70. CrossRef
Backgrounds/Aims Despite advances in antiviral therapy for hepatitis C virus (HCV) infection, hepatocellular carcinoma (HCC) still develops even after sustained viral response (SVR) in patients with advanced liver fibrosis or cirrhosis. This meta-analysis investigated the predictive performance of vibration-controlled transient elastography (VCTE) and fibrosis 4-index (FIB-4) for the development of HCC after SVR.
Methods We searched PubMed, MEDLINE, EMBASE, and the Cochrane Library for studies examining the predictive performance of these tests in adult patients with HCV. Two authors independently screened the studies’ methodological quality and extracted data. Pooled estimates of sensitivity, specificity, and area under the curve (AUC) were calculated for HCC development using random-effects bivariate logit normal and linear-mixed effect models.
Results We included 27 studies (169,911 patients). Meta-analysis of HCC after SVR was possible in nine VCTE and 15 FIB-4 studies. Regarding the prediction of HCC development after SVR, the pooled AUCs of pre-treatment VCTE >9.2–13 kPa and FIB-4 >3.25 were 0.79 and 0.73, respectively. VCTE >8.4–11 kPa and FIB-4 >3.25 measured after SVR maintained good predictive performance, albeit slightly reduced (pooled AUCs: 0.77 and 0.70, respectively). The identified optimal cut-off value for HCC development after SVR was 12.6 kPa for pre-treatment VCTE. That of VCTE measured after the SVR was 11.2 kPa.
Conclusions VCTE and FIB-4 showed acceptable predictive performance for HCC development in patients with HCV who achieved SVR, underscoring their utility in clinical practice for guiding surveillance strategies. Future studies are needed to validate these findings prospectively and validate their clinical impact.
Citations
Citations to this article as recorded by
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng Clinical and Molecular Hepatology.2025; 31(1): e23. CrossRef
Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2025; 31(1): 261. CrossRef
Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim Medicina.2025; 61(9): 1601. CrossRef
Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines Masaaki Mino, Eiji Kakazu, Tatsuya Kanto Gut and Liver.2025; 19(5): 651. CrossRef
Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C Yu Rim Lee, Hyun Young Woo, Young Oh. Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Min Kyu Kang, Jeong Eun Song, Byoung Kuk Jang, Changhyeong Lee, Byung Seok Kim, Jae Seok Hwang, Woo Jin Chung, Jeong Heo, Nae‐Yun Heo, Seung Ha Park, Jun Sik Yoon, J Journal of Gastroenterology and Hepatology.2025; 40(10): 2568. CrossRef
Diagnostic possibilities of perfusion computed tomography in assessing fibrosis regression in patients with chronic viral hepatitis C: a prospective study E. A. Ioppa, O. S. Tonkikh, I. Yu. Degtyarev, V. D. Zavadovskaya, E. S. Garganeeva Diagnostic radiology and radiotherapy.2025; 16(3): 65. CrossRef
Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography Han Ah Lee Clinical Ultrasound.2024; 9(2): 70. CrossRef
Background/Aims Although important, clinically significant liver fibrosis is often overlooked in the general population. We aimed to examine the prevalence of clinically significant liver fibrosis using noninvasive tests (NITs) in the general population.
Methods We collected data from four databases (MEDLINE, Embase, Cochrane Library, and KoreaMed) from inception to June 13, 2023. Original articles reporting the prevalence of clinically significant liver fibrosis in the general population were included. The Stata metaprop function was used to obtain the pooled prevalence of liver fibrosis with NITs in the general population.
Results We screened 6,429 articles and included 45 eligible studies that reported the prevalence of clinically significant liver fibrosis in the general population. The prevalence of advanced liver fibrosis, using the high probability cutoff of the fibrosis-4 (FIB-4) index, was 2.3% (95% confidence interval [CI], 1.2–3.7%). The prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, assessed using vibration-controlled transient elastography (VCTE) among the general population, was 7.3% (95% CI, 5.9–8.8%), 3.5% (95% CI, 2.7–4.5), and 1.2% (95% CI, 0.8–1.8%), respectively. Region-based subgroup analysis revealed that the highest prevalence of advanced fibrosis using the high probability cutoff of the FIB-4 index was observed in the American region. Furthermore, the American region exhibited the highest prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, using VCTE.
Conclusions Previously undiagnosed clinically significant liver fibrosis is found in the general population through NITs. Future research is necessary to stratify the risk in the general population.
Citations
Citations to this article as recorded by
Spotting undiagnosed significant liver fibrosis in the general population: impact on subsequent clinical care: Editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis” Nana Peng, Mary Yue Wang, Sherlot Juan Song, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2025; 31(1): 256. CrossRef
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis” Hee Yeon Kim, Miyoung Choi, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e48. CrossRef
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population” Wei Feng, Qile Wang, Qingwang Ye Clinical and Molecular Hepatology.2025; 31(1): e21. CrossRef
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis” Hee Yeon Kim, Miyoung Choi, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e105. CrossRef
Hypoxia-inducible factor-1 alpha (HIF-1α) inhibitor AMSP-30 m attenuates CCl4-induced liver fibrosis in mice by inhibiting the sonic hedgehog pathway Lili Lu, Yuchen Ma, Qing Tao, Jing Xie, Xiao Liu, Yongkang Wu, Yang Zhang, Xiuli Xie, Mingming Liu, Yong Jin Chemico-Biological Interactions.2025; 413: 111480. CrossRef
Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng Clinical and Molecular Hepatology.2025; 31(2): 620. CrossRef
Simple Clinical Prediction Rules for Identifying Significant Liver Fibrosis: Evaluation of Established Scores and Development of the Aspartate Aminotransferase-Thrombocytopenia-Albumin (ATA) Score Puwitch Charoenchue, Jiraporn Khorana, Apichat Tantraworasin, Suwalee Pojchamarnwiputh, Wittanee Na Chiangmai, Amonlaya Amantakul, Taned Chitapanarux, Nakarin Inmutto Diagnostics.2025; 15(9): 1119. CrossRef
Targeting endoplasmic reticulum proteostasis in liver fibrosis: From signaling mechanisms to therapeutic opportunities Yawei Kong, Zhengyang Chen, Zhentian Nie, Wei Chen Pharmacological Research.2025; 217: 107823. CrossRef
Decoding the hepatic fibrosis-hepatocellular carcinoma axis: from mechanisms to therapeutic opportunities Anqi Lin, Minying Xiong, Bufu Tang, Aimin Jiang, Junyi Shen, Zaoqu Liu, Quan Cheng, Jian Zhang, Peng Luo Hepatology International.2025; 19(4): 732. CrossRef
Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests Huiyul Park, Eileen L. Yoon, Mimi Kim, Ji-hyeon Park, Ramsey Cheung, Jeong-Yeon Cho, Hye-Lin Kim, Dae Won Jun Scientific Reports.2025;[Epub] CrossRef
Senkyunolide I targets CXCR4 to attenuate liver fibrosis via suppression of the NLRP3/GSDMD pathway Kexin Wang, Yuxin Yang, Bingjie Yue, Mengyang Li, Chu Chen, Junrong Du, Fangyi Long International Immunopharmacology.2025; 164: 115348. CrossRef
Chronic liver disease and radiation-induced second primary liver malignancy: a retrospective cohort based on SEER database 2010–2021 Asmaa Ellaithy, Aya Serageldeen, Alhareth Alhusban, Mariam Emad Seif, Mahmoud Essam Abdelhamid, Bushra Al-Shaikh, Asmaa Sayed Ibrahim, Eslam Mohamed Elshennawy, Ibrahim Ellaithy Annals of Medicine & Surgery.2025; 87(8): 4742. CrossRef
PREVALENCE OF VARIOUS ETIOPATHOGENIC VARIANTS OF CHRONIC DIFFUSE LIVER DISEASES B. Sakhova, A. Oshibayeva, N. Nuskabayeva, E. Iskandirova, Zh. Rsalieva, N. Karabayev, L. Karimova, L. Ozbakyr Medicine and ecology.2025; (3): 35. CrossRef
Association between gestational diabetes mellitus and liver cirrhosis and fibrosis: A population‐based cohort study and risk factor analysis Tan‐Tzu Lo, Wan‐Ting Huang, Chia‐Lung Shih, Pensee Wu International Journal of Gynecology & Obstetrics.2025;[Epub] CrossRef
Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis Jonghyun Kim, Takanori Ito, Taeang Arai, Masanori Atsukawa, Miwa Kawanaka, Hidenori Toyoda, Takashi Honda, Ming-Lung Yu, Eileen L. Yoon, Dae Won Jun, Kyungjoon Cha, Mindie H. Nguyen Diagnostics.2024; 14(22): 2500. CrossRef
Background/Aims The Fibrosis-4 index (FIB-4) is a noninvasive test widely used to rule out advanced liver fibrosis (AF) in patients with nonalcoholic fatty liver disease (NAFLD). However, its diagnostic accuracy in NAFLD patients with type 2 diabetes mellitus (T2DM) is controversial due to the high prevalence of AF in this population.
Methods Research focusing on the diagnostic accuracy of FIB-4 for liver fibrosis as validated by liver histology in NAFLD patients with T2DM was included, and 12 studies (n=5,624) were finally included in the meta-analysis. Sensitivity, specificity, hierarchical summary receiver operating characteristic (HSROC), positive predictive values (PPVs), and negative predictive values (NPVs) at low cutoffs (1.3–1.67) and high cutoffs (2.67–3.25) for ruling in and out AF were calculated.
Results At low cutoffs, the meta-analysis revealed a sensitivity of 0.74, specificity of 0.62, and HSROC of 0.75. At high cutoffs, the analysis showed a sensitivity of 0.33, specificity of 0.92, and HSROC of 0.85, suggesting FIB-4 as useful for identifying or excluding AF. In subgroup analyses, high mean age and F3 prevalence were associated with lower sensitivity. The calculated NPV and PPV were 0.82 and 0.49 at low cutoffs, whereas the NPV was 0.28 and the PPV was 0.70 at high cutoffs. There were insufficient estimated NPVs <0.90 at a hypothesized prevalence of AF >30% at an FIB-4 cutoff range of 1.3–1.67.
Conclusions Collectively, FIB-4 has moderate diagnostic accuracy for identifying or excluding AF in NAFLD patients with T2DM, but more evidence must be accumulated due to the limited number of currently reported studies and their heterogeneity.
Citations
Citations to this article as recorded by
Prognostic value of the FIB-4 index in patients with myocardial infarction with non-obstructive coronary arteries Wei Zhang, Yuqi Chen, Liu Zhu, Siliang Peng, Mengchao Jin, Jiayu Yin International Journal of Cardiology.2026; 445: 134045. CrossRef
Reply to: “A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?” Moon Haeng Hur, Jeong-Hoon Lee Journal of Hepatology.2025; 82(3): e143. CrossRef
The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang Clinical and Molecular Hepatology.2025; 31(1): e25. CrossRef
Non-Invasive Liver Fibrosis Test Using Shear Wave Elastography Ji Won Han The Korean Journal of Medicine.2025; 100(1): 26. CrossRef
Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liv Ji Won Han, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(2): e152. CrossRef
Targeting endoplasmic reticulum proteostasis in liver fibrosis: From signaling mechanisms to therapeutic opportunities Yawei Kong, Zhengyang Chen, Zhentian Nie, Wei Chen Pharmacological Research.2025; 217: 107823. CrossRef
Comparison of FIB-4, APRI and AST/ALT ratio with FibroScan in patients with NAFLD and type 2 diabetes: a single-center study from Bangladesh Muhammad Shah Alam, Syeda Tanzina Kalam, Monirul Islam Khan, Jabed Ahmed, Rahul Saha, A. B. M. Kamrul-Hasan Egyptian Liver Journal.2025;[Epub] CrossRef
Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD Mitchell P. Wilson, Gavin Low, Abdel-Aziz Shaheen, Andreu F. Costa, An Tang, Emily Pang, Silvia Chang, Alexandra Medellin, Jérémy Dana, Noam Millo, Ania Kielar, Li Xin Zhang, Toni Whitaker, Mark Swain, Victoria Leung, Daisy Fung, Casey Hurrell, Christophe Canadian Association of Radiologists Journal.2025;[Epub] CrossRef
Impact of a high dietary fiber cereal meal intervention on the progression of liver fibrosis in T2DM with MASLD Xi-Shuang Chen, Hui-Zhen Liu, Fang Huang, Jian Meng, Jing-Xian Fang, Yu Han, Hui-Ming Zou, Qing Gu, Xue Hu, Qian-Wen Ma, Yue-Xia Han, Sui-Jun Wang Frontiers in Endocrinology.2025;[Epub] CrossRef
Association between fibrosis-4 index and coronary heart disease: a population-based study Pan Jia, Mamajan Annamyradova, Genhao Fan, Qizhen Zhang, Yankun Song, Qiaozhi Li, Minghao Liu, Zuoying Xing, Yongxia Wang BMC Cardiovascular Disorders.2025;[Epub] CrossRef
Forns index and fatty liver index, but not FIB-4, are associated with indices of glycaemia, pre-diabetes and type 2 diabetes: analysis of The Maastricht Study Leen Heyens, Hanna Kenjic, Pieter Dagnelie, Casper Schalkwijk, Coen Stehouwer, Steven Meex, Jeroen Kooman, Otto Bekers, Marleen van Greevenbroek, Hans Savelberg, Geert Robaeys, Bastiaan de Galan, Annemarie Koster, Martien van Dongen, Simone Eussen, Ger Ko BMJ Open Gastroenterology.2024; 11(1): e001466. CrossRef
Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi
Clin Mol Hepatol 2024;30(Suppl):S106-S116. Published online July 23, 2024
Backgrounds/Aims Accurate diagnosis of significant liver fibrosis in patients with chronic hepatitis B (CHB) is crucial when determining whether to initiate antiviral treatment (AVT). We conduct a meta-analysis to assess the diagnostic performance of vibration-controlled transient elastography (VCTE) for significant liver fibrosis in AVT-naïve CHB patients with serum alanine transaminase (ALT) levels within 5-fold the upper limit of normal (ULN).
Methods The Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases were searched to identify studies that compared the performance of VCTE and liver biopsy (reference standard) when diagnosing significant liver fibrosis (≥F2) in AVT-naïve CHB patients with ALT within 5-fold the ULN. A hierarchical summary receiver operating characteristic curve (HSROC) and bivariate model were performed to evaluate the diagnostic performance of VCTE in the meta-analysis.
Results Eight studies (2,003 patients) were included. The summary sensitivity and specificity for diagnosis of significant liver fibrosis were 0.78 (95% confidence interval [CI], 0.66–0.86) and 0.72 (95% CI, 0.60–0.82), respectively. The HSROC for the diagnosis of significant liver fibrosis was 0.81 (95% CI, 0.72–0.86). The optimal cutoff value of VCTE for diagnosis of significant liver fibrosis was 7.7 kPa with a sensitivity of 0.64 (95% CI, 0.50–0.76) and specificity of 0.83 (95% CI, 0.72–0.90).
Conclusions Our study demonstrated that VCTE has an acceptable diagnostic performance for significant liver fibrosis in AVT-naïve CHB patients with ALT within 5-fold the ULN.
Citations
Citations to this article as recorded by
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K Journal of Gastroenterology and Hepatology.2025; 40(6): 1595. CrossRef
Assessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers? Deniz Borcak, Zuhal Yesilbag, Yusuf Emre Ozdemir, Adile Sevde Demir, Esra Salim Dogdas, Aysegul Inci Sezen, Esra Canbolat Unlu, Sevtap Senoglu, Hayat Kumbasar Karaosmanoglu, Kadriye Kart Yasar Journal of Clinical Medicine.2025; 14(22): 8164. CrossRef
Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease Jung Hwan Yu The Korean Journal of Medicine.2024; 99(5): 232. CrossRef
Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography Mi Na Kim The Korean Journal of Gastroenterology.2024; 84(5): 201. CrossRef
Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography Han Ah Lee Clinical Ultrasound.2024; 9(2): 70. CrossRef
Young-Joo Jin, Hee Yeon Kim, Young Ju Suh, Chae Hyeon Lee, Jung Hwan Yu, Mi Na Kim, Ji Won Han, Han Ah Lee, Jihyun An, Young Eun Chon, Dae Won Jun, Miyoung Choi, Seung Up Kim
Clin Mol Hepatol 2024;30(Suppl):S159-S171. Published online July 23, 2024
Backgrounds/Aims Liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE) can assess fibrotic burden in chronic liver diseases. The systematic review and meta-analysis was conducted to determine whether LSM using VCTE can predict the risk of development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients.
Methods A systematic literature search of the Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases (from January 2010 to June 2023) was conducted. Of the 1,345 individual studies identified, 10 studies that used VCTE were finally registered. Hazard ratios (HRs) and the 95% confidence intervals (CIs) were considered summary estimates of treatment effect sizes of ≥11 kilopascal (kPa) standard for HCC development. Meta-analysis was performed using the restricted Maximum Likelihood random effects model.
Results Among the ten studies, data for risk ratios for HCC development could be obtained from nine studies. When analyzed for the nine studies, the HR for HCC development was high at 3.33 (95% CI, 2.45–4.54) in CHB patients with a baseline LSM of ≥11 kPa compared to patients who did not. In ten studies included, LSM of ≥11 kPa showed the sensitivity and specificity for predicting HCC development were 61% (95% CI, 50–71%) and 78% (95% CI, 66–86%), respectively, and the diagnostic accuracy was 0.74 (95% CI, 0.70–0.77).
Conclusions The risk of HCC development was elevated in CHB patients with VCTE-determined LSM of ≥11 kPa. This finding suggests that VCTE-determined LSM values may aid the risk prediction of HCC development in CHB patients.
Citations
Citations to this article as recorded by
The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: S Mirko Zoncapè, Emmanuel A. Tsochatzis Clinical and Molecular Hepatology.2025; 31(1): 268. CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B Jiwon Yang, Mark D. Muthiah, Won-Mook Choi Current Hepatology Reports.2025;[Epub] CrossRef
Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K Journal of Gastroenterology and Hepatology.2025; 40(6): 1595. CrossRef
Discovering the metabolic pathway of liver disease by breath mass spectrometry combined with machine learning Xuanzhu Li, Wenbo Zhang, Tongtong Yang, Ying Zhang, Rui Su Journal of Pharmaceutical and Biomedical Analysis.2025; 265: 116988. CrossRef
Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C Beom Kyung Kim Journal of Gastroenterology and Hepatology.2025; 40(8): 1855. CrossRef
Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis” Haiyu Wang, Jinjun Chen Clinical and Molecular Hepatology.2025;[Epub] CrossRef
EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection Shichuan Tang, Tingfeng Huang, Ruijing Tang, Kongying Lin, Cong Luo, Yubing Shen, Kailing Zhang, Yidan Tang, Jie Kong, Zhenwei Chen, Jun Fu, Qizhu Lin, Luobin Guo, Yeye Wu, Yuntong Li, Jianxi Zhang, Zhenghong Sun, Penghui You, Daichang Zhang, Yanxin Chen, Gut.2025; : gutjnl-2025-335449. CrossRef
The Evolving Application of Ultrasound in the Precision Management of Small Hepatocellular Carcinoma Xin Guan, Xinyuan Hu, Hong Han, Dezhi Zhang, Huixiong Xu Advanced Ultrasound in Diagnosis and Therapy.2025; 9(4): 375. CrossRef
Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George
Clin Mol Hepatol 2024;30(3):436-448. Published online April 16, 2024
Background/Aims The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis plus defined markers of metabolic dysfunction, irrespective of concurrent liver disease. We aimed to determine the total global prevalence of MAFLD in HCC cohorts (total-MAFLD), including the proportion with MAFLD as their sole liver disease (single-MAFLD), and the proportion of those with concurrent liver disease where MAFLD was a contributary factor (mixed-MAFLD).
Methods This systematic review and meta-analysis included studies systematically ascertaining MAFLD in HCC cohorts, defined using international expert panel criteria including ethnicity-specific BMI cut-offs. A comparison of clinical and tumour characteristics was performed between single-MAFLD, mixed-MAFLD, and non-MAFLD HCC.
Results 22 studies (56,565 individuals with HCC) were included. Total and single-MAFLD HCC prevalence was 48.7% (95% confidence interval [CI] 34.5–63.0%) and 12.4% (95% CI 8.3–17.3%), respectively. In HCC due to chronic hepatitis B, C, and alcohol-related liver disease, mixed-MAFLD prevalence was 40.0% (95% CI 30.2–50.3%), 54.1% (95% CI 40.4–67.6%) and 64.3% (95% CI 52.7–75.0%), respectively. Mixed-MAFLD HCC had significantly higher likelihood of cirrhosis and lower likelihood of metastatic spread compared to single-MAFLD HCC, and a higher platelet count and lower likelihood of macrovascular invasion compared to non-MAFLD HCC.
Conclusions MAFLD is common as a sole aetiology, but more so as a co-factor in mixed-aetiology HCC, supporting the use of positive diagnostic criteria.
Citations
Citations to this article as recorded by
Association of the Number of Concurrent Metabolic Syndrome Risk Factors with Textbook Outcomes Following Liver Resection for Patients with Hepatocellular Carcinoma: A Multicenter Study Zhan-Cheng Qiu, Jun-Long Dai, Yu Zhang, Fei Xie, Yu Yu, Shu-Sheng Leng, Tian-Fu Wen, Chuan Li Annals of Surgical Oncology.2025; 32(1): 399. CrossRef
Deciphering the roles of neddylation modification in hepatocellular carcinoma: Molecular mechanisms and targeted therapeutics Wenxin Wu, Xuanyi Wang, Ruijie Ma, Shuhong Huang, Hongguang Li, Xinxing Lyu Genes & Diseases.2025; 12(4): 101483. CrossRef
Alterations of Krüppel-like Factor Signaling and Potential Targeted Therapy for Hepatocellular Carcinoma Rongfei Fang, Chunxiu Sha, Qun Xie, Dengfu Yao, Min Yao Anti-Cancer Agents in Medicinal Chemistry.2025; 25(2): 75. CrossRef
Associations of MAFLD subtypes and air pollutants with multi-system morbidity and all-cause mortality: A prospective cohort study Jingyi Zhang, Shanshan Ran, Shengtao Wei, Fei Tian, Lan Chen, Zijun Yang, Ge Chen, Hualiang Lin Ecotoxicology and Environmental Safety.2025; 291: 117893. CrossRef
Global burden and international disparities in NASH-associated liver Cancer: mortality trends (1990–2021) and future projections to 2045 Qilong Nie, Yongwen Jiang, Mingyang Li, Qiuyan Liang, Xiaoai Mo, Tengyu Qiu, Qunfang Jiang, Kaizhou Huang, Youqing Xie, Ying Chen, Xiaojun Ma, Jianhong Li, Kaiping Jiang Frontiers in Public Health.2025;[Epub] CrossRef
Exploring emerging frontiers in hepatology: iLIVER's continuing journey Ming-Da Wang, Xin-Fei Xu, Lei Cai, Tian Yang iLIVER.2025; 4(1): 100148. CrossRef
A review of image guidance and localization methods for liver puncture robots Yongde Zhang, Jiabin Yang, Xuequan Huang, Chuang He Journal of Robotic Surgery.2025;[Epub] CrossRef
Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon Liver International.2025;[Epub] CrossRef
Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis Sahana Shetty, Renuka Suvarna, Vanessa Ambrose Fistus, Shivam Modi, Joseph M Pappachan World Journal of Hepatology.2025;[Epub] CrossRef
Characterisation of non-cirrhotic MAFLD-related hepatocellular carcinoma: a retrospective cohort study Shadi Zerehpooshnesfchi, Fatema Safri, Ziyan Pan, Romario Nguyen, Lawrence Yuen, Vincent Lam, Christopher Nahm, Tony Pang, Golo Ahlenstiel, Jacob George, Mohammed Eslam, Liang Qiao Therapeutic Advances in Chronic Disease.2025;[Epub] CrossRef
Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide Yuki Oe, Takashi Omori, Eriko Aimono, Shin Furukawa, Hirohiko Kitakawa, Masatoshi Tateno, Kiyoshi Sakai, Kyu Yong Cho Frontiers in Endocrinology.2025;[Epub] CrossRef
Trends and visualization analysis of research on MASLD-Related hepatocellular carcinoma: a bibliometric analysis Hongkun Yin, Xusheng Zhang, Qi Wang Discover Oncology.2025;[Epub] CrossRef
Overweight and Helicobacter pylori infection: a correlation in metabolic dysfunction-associated fatty liver disease Xu Chen, Jiayue Fu, Kejia Jin, Zixuan Yang, Yidan Qian, Kehan Mei, Yihan Wang, Jialei Min, Yilin Du, Zaisheng Zhu, Shengcun Li Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Hemostatic alterations in metabolic dysfunction-associated steatotic liver disease (MASLD) and their link to venous thromboembolism (VTE) David E. González-Mendoza, Francisco Fernández-Nogueira, Misael Uribe, Norberto C. Chávez-Tapia, Natalia Nuño-Lámbarri Thrombosis Research.2025; 253: 109395. CrossRef
Rewriting the MASLD‐associated hepatocellular carcinoma script: Targeting epigenetics and metabolism Chiara Aiello, Eric Felli, Teresa Musarra, Lorenzo Nevi, Annamaria Altomare, Jordi Gracia‐Sancho, Andrea Baiocchini, Simone Carotti International Journal of Cancer.2025; 157(10): 1991. CrossRef
Role of mac-2 binding protein glycosylation isomer in predicting fibrosis in patients with metabolic dysfunction-associated steatotic liver disease Thuy Thi Thu Pham, Dat Tan Ho, Chanh Pham, Hoan Phan, Bieu Phu, Toan Nguyen, Dang Nguyen, Hai Thanh Phan, Khue Minh Nguyen World Journal of Hepatology.2025;[Epub] CrossRef
The triadic relationship between nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease: From molecular mechanisms to clinical management Yuxi Jin, Mohammed Alissa, Ahmed Ezzat Ahmed, Amin A. Al-Doaiss, Naif Asiri, Yasser Assiri, Shahid Ullah Khan, Munir Ullah Khan, Samuel Joseph Current Problems in Cardiology.2025; 50(11): 103170. CrossRef
Astragaloside IV alleviates metabolic associated fatty liver disease by regulating ferroptosis via the SLC7A11/GPX4 pathway Sitong Chen, Hanying Xu, Zipei Zhang, Xiaonan Li, Xiaolei Tang, Dashi Ying Chinese Journal of Analytical Chemistry.2025; : 100625. CrossRef
Exploring the Link Between Irritable Bowel Syndrome and Chronic Diseases: A Narrative Overview Sneha Reddy, Savithri C. Veluri Academic Medicine & Surgery.2025;[Epub] CrossRef
Fibrosis Severity in MASLD Determines the Predictive Value of Lp-PLA2 for Carotid Atherosclerosis in Type 2 Diabetes: A Cross-Sectional Study Junzhao Ye, Rui Song, Xiaorong Gong, Xin Li, Congxiang Shao, Bihui Zhong Biomedicines.2025; 13(10): 2431. CrossRef
Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Lipid metabolism in cancer cells: Its role in hepatocellular carcinoma progression and therapeutic resistance Tin Lok Wong, Yanshu Kong, Stephanie Ma Hepatology Communications.2025;[Epub] CrossRef
Hepatocellular carcinoma: modern aspects of interdisciplinary management. Part 1. Epidemiology, risk factors, diagnosis Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova GASTROENTEROLOGY.2025; 59(3): 206. CrossRef
Protective effect and mechanisms of puerarin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of animal studies Xiang-yun Zou, Yu-cheng Yang, Xue-han Liu, Wen-ying Qi, Xiao-bin Zao, Xiao-ke Li, Yong’an Ye Pharmacological Research.2025; 222: 108024. CrossRef
A comprehensive bibliometric and visual analysis of tumor-associated macrophages in hepatocellular carcinoma GuanBo Zhang, Gang Li, JinSong Li, Jie Zhang, Zhi Yang, Lin Yang, ShiJie Jiang, ShiFan Zhu, JiaXing Wang Discover Oncology.2025;[Epub] CrossRef
Targeting Ferroptosis: New Insights and Therapeutic Advances in MAFLD Complicating T2DM Fang Yao, Gaochao Wang, Fan Ning, Yanbo Shi Frontiers in Bioscience-Landmark.2025;[Epub] CrossRef
Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Wolf in Sheep's Clothing Xixi Fang, Chenhao Xu, Jun Lu, Runzhou Zhuang, Xiao Xu, Xuyong Wei Cell Biochemistry and Function.2025;[Epub] CrossRef
Splanchnic inflammatory syndrome and the not-so-silent risk of cancer Richard C Semelka MD, Miguel Ramalho MD Gastroenterology & Hepatology: Open access.2024; 15(3): 63. CrossRef
Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 705. CrossRef
Unraveling the epidemiology of metabolic dysfunction-associated liver cancer: Insights from mixed etiologies, regional variations, and gender disparities Gong Feng, Ya-Fei Fan, Ru-Xin Li, Giovanni Targher, Christopher D. Byrne, Ming-Hua Zheng iLIVER.2024; 3(3): 100113. CrossRef
Impact of occult hepatitis B virus infection and high-fat diet on hepatocellular carcinoma development Kun Chen, Chunfeng Qu Hepatoma Research.2024;[Epub] CrossRef
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George Hepatology International.2024; 18(6): 1740. CrossRef
Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A sy Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 965. CrossRef
Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis Muhammed Shabil, Mahalaqua Nazli Khatib, Suhas Ballal, Pooja Bansal, Balvir S. Tomar, Ayash Ashraf, M. Ravi Kumar, Aashna Sinha, Pramod Rawat, Abhay M. Gaidhane, Sanjit Sah, Afukonyo Shidoiku Daniel, Ambanna Yappalparvi, Ganesh Bushi BMC Endocrine Disorders.2024;[Epub] CrossRef
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi, Shukui Qin, Haitao Zhao, Motoyuki Otsuka, Sadahisa Ogasawara, Jacob George, Pierce K. H. Chow, Jianqiang Cai, Shuichiro Shiina, Naoya Kato, Osamu Yokosuka, Kyoko Oura, Thomas Yau, Stephen L. Chan, Min Hepatology International.2024; 18(6): 1661. CrossRef
Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol 2024;30(3):345-359. Published online March 12, 2024
Background/Aims Atezolizumab plus bevacizumab (ATE+BEV) therapy has become the recommended first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) because of favorable treatment responses. However, there is a lack of data on sequential regimens after ATE+BEV treatment failure. We aimed to investigate the clinical outcomes of patients with advanced HCC who received subsequent systemic therapy for disease progression after ATE+BEV.
Methods This multicenter, retrospective study included patients who started second-line systemic treatment with sorafenib or lenvatinib after HCC progressed on ATE+BEV between August 2019 and December 2022. Treatment response was assessed using the Response Evaluation Criteria in Solid Tumors (version 1.1.). Clinical features of the two groups were balanced through propensity score (PS) matching.
Results This study enrolled 126 patients, 40 (31.7%) in the lenvatinib group, and 86 (68.3%) in the sorafenib group. The median age was 63 years, and males were predominant (88.1%). In PS-matched cohorts (36 patients in each group), the objective response rate was similar between the lenvatinib- and sorafenib-treated groups (5.6% vs. 8.3%; P=0.643), but the disease control rate was superior in the lenvatinib group (66.7% vs. 22.2%; P<0.001). Despite the superior progression- free survival (PFS) in the lenvatinib group (3.5 vs. 1.8 months, P=0.001), the overall survival (OS, 10.3 vs. 7.5 months, P=0.353) did not differ between the two PS-matched treatment groups.
Conclusions In second-line therapy for unresectable HCC after ATE+BEV failure, lenvatinib showed better PFS and comparable OS to sorafenib in a real-world setting. Future studies with larger sample sizes and longer follow-ups are needed to optimize second-line treatment.
Citations
Citations to this article as recorded by
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma Bruno Sangro, Josepmaria Argemi, Maxime Ronot, Valerie Paradis, Tim Meyer, Vincenzo Mazzaferro, Peter Jepsen, Rita Golfieri, Peter Galle, Laura Dawson, Maria Reig Journal of Hepatology.2025; 82(2): 315. CrossRef
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo Journal of Cancer Research and Clinical Oncology.2025;[Epub] CrossRef
Treatment for hepatocellular carcinoma after immunotherapy Landon L. Chan, Tsz Tung Kwong, Johnny C.W. Yau, Stephen L. Chan Annals of Hepatology.2025; 30(2): 101781. CrossRef
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study Christian Möhring, Moritz Berger, Farsaneh Sadeghlar, Xin Zhou, Taotao Zhou, Malte Benedikt Monin, Kateryna Shmanko, Sabrina Welland, Friedrich Sinner, Birgit Schwacha-Eipper, Ulrike Bauer, Christoph Roderburg, Angelo Pirozzi, Najib Ben Khaled, Peter Schr Cancers.2025; 17(6): 972. CrossRef
Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort Najib Ben Khaled, Valentina Zarka, Bernard Hobeika, Julia Schneider, Monika Rau, Alexander Weich, Hans Benno Leicht, Liangtao Ye, Ignazio Piseddu, Michael T. Dill, Arne Kandulski, Matthias Pinter, Ursula Ehmer, Peter Schirmacher, Jens U. Marquardt, Julia Alimentary Pharmacology & Therapeutics.2025; 61(11): 1755. CrossRef
Application of the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique in conversion therapy for hepatocellular carcinoma Jingyun Ning, Cao Dai, Qin Liu, Haoming Lin, Rui Zhang British Journal of Surgery.2025;[Epub] CrossRef
Recent advances in polydopamine-coated metal–organic frameworks for cancer therapy Jingchao He, Guangtian Wang, Yongfang Zhou, Bin Li, Pan Shang Frontiers in Bioengineering and Biotechnology.2025;[Epub] CrossRef
Targeting STAT3 by erianin to overcome sorafenib resistance in hepatocellular carcinoma: Integrated network pharmacology with molecular docking, dynamics simulations, and in vitro validation Zixian Liu, Ruoning Qian, Yuanchao Feng, Ruogu Qi, Zhengguang Zhang, Fuqiong Zhou Biochemical and Biophysical Research Communications.2025; 778: 152348. CrossRef
PEGylated liposomal metformin overcomes pharmacokinetic barriers to trigger potent mitochondrial disruption and cell cycle arrest in hepatocellular carcinoma Zeinab A. Elzanaty, Medhat W. Shafaa, Seifeldin Elabed, Mohamed M. Omran Scientific Reports.2025;[Epub] CrossRef
Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab Jaekyung Cheon, Baek-Yeol Ryoo, Hong Jae Chon, Hyung-Don Kim, Min-Hee Ryu, Kyu-Pyo Kim, Beodeul Kang, Richard S. Finn, Stephen Lam Chan, Changhoon Yoo Liver Cancer.2025; 14(4): 446. CrossRef
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab Heechul Nam, Dong Yun Kim, Do Young Kim, Ji Hoon Kim, Chang Wook Kim, Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Soon Kyu Lee, Jung Hyun Kwon, Soon Woo Nam, Ahlim Lee, Do Seon Song, U Im Chang, Hepatology.2025;[Epub] CrossRef
Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab Hyung-Don Kim, Sun Jin Sym, Hong Jae Chon, Moonho Kim, Jung Hun Kang, Baek-Yeol Ryoo, Choong-kun Lee, Joohyun Hong, Hyewon Ryu, Woo Kyun Bae, Hyeyeong Kim, Hyunho Kim, Jin Won Kim, Tae-Yong Kim, Changhoon Yoo Journal of Hepatology.2025;[Epub] CrossRef
Lenvatinib versus sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: the LEVIATHAN Study. Pasquale Lombardi, Jung Sun Kim, Giulia F. Manfredi, Ciro Celsa, Claudia A.M. Fulgenzi, Antonio D’Alessio, Bernardo Stefanini, Niraj C. Doshi, Emily Warmington, Thomas U. Marron, Matthias Pinter, Bernhard Scheiner, Beodeul Kang, Ho Yeong Lim, Wei-Fan Hsu, JHEP Reports.2025; : 101595. CrossRef
Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma Kazuki Maesaka, Hayato Hikita, Yuki Tahata, Chinatsu Nishioka, Machiko Kai, Kumiko Shirai, Kazuhiro Murai, Yuki Makino, Yoshinobu Saito, Takahiro Kodama, Kazuyoshi Ohkawa, Masanori Miyazaki, Yasutoshi Nozaki, Takayuki Yakushijin, Ryotaro Sakamori, Nobuyuk Journal of Gastroenterology.2025;[Epub] CrossRef
The potential of lenvatinib in breast cancer therapy Yuefeng Shang, Tong Liu, Wenjing Wang Medical Oncology.2024;[Epub] CrossRef
Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-xL, display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity Xiaoyi Zhang, Yachuan Tao, Zhongli Xu, Biao Jiang, Xiaobao Yang, Taomin Huang, Wenfu Tan Biochemical Pharmacology.2024; 230: 116542. CrossRef
Second-line systemic therapy after atezolizumab plus bevacizumab: Is it time to boldly go beyond the known? Edoardo G. Giannini Digestive and Liver Disease.2024; 56(12): 2077. CrossRef
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study” Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim Clinical and Molecular Hepatology.2024; 30(4): 1005. CrossRef
Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma Ji Yeon Lee, Jaejun Lee, Suho Kim, Jae-sung Yoo, Ji Hoon Kim, Keungmo Yang, Ji Won Han, Jeong Won Jang, Jong Yong Choi, Seung Kew Yoon, Ho Jong Chun, Jung Suk Oh, Pil Soo Sung Frontiers in Oncology.2024;[Epub] CrossRef
Background/Aims Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake.
Methods Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors.
Results Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9–8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122–8.051; P=0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P=0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404–7.228; P=0.47).
Conclusions Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.
Citations
Citations to this article as recorded by
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs Emi Sometani, Hayato Hikita, Kazuhiro Murai, Hidenori Toyoda, Satoshi Tanaka, Tsugiko Oze, Jihyun Sung, Akiyoshi Shimoda, Makoto Fukuoka, Satoshi Shigeno, Keisuke Fukutomi, Kumiko Shirai, Yuki Tahata, Yoshinobu Saito, Akira Nishio, Kunimaro Furuta, Takahi Hepatology Research.2025; 55(1): 22. CrossRef
Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B Xinrong Zhang, Vy H Nguyen, Leslie Yeeman Kam, Scott D Barnett, Linda Henry, Ramsey Cheung, Mindie H Nguyen The Journal of Infectious Diseases.2025; 231(4): 1079. CrossRef
Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B Navavee Uman, Apichat Kaewdech, Pimsiri Sripongpun, Naichaya Chamroonkul, Teerha Piratvisuth Gastroenterology Report.2025;[Epub] CrossRef
Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection Chih-Jan Ko American Journal of Cancer Research.2025; 15(2): 737. CrossRef
Study on Ultrasound-Assisted Diagnosis of CHB Complicated with NAFLD Hepatic Fibrosis Based on Deep Learning Xiuling Huang, Shan Huang, Changfeng Dong, Nuo Chen, Yuxuan Wang, Changmiao Wang, Yongquan Zhang, Cheng Feng Journal of Imaging Informatics in Medicine.2025;[Epub] CrossRef
The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease Mao-Ping Li, Kai-Zhong Luo Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 476. CrossRef
Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis Qianqian Zhu, Chengde Su, Mingdan Li, Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Ping Yang Infectious Diseases and Therapy.2025; 14(8): 1599. CrossRef
Chronic hepatitis B: Is it time for expanded antiviral treatment? Manish Manrai, Atul A Jha, Aditya V Pachisia, Saurabh Dawra World Journal of Virology.2025;[Epub] CrossRef
Hepatocellular carcinoma risk stratification to identify patients suitable for intensive surveillance in viral hepatitis: the SELECT score Yeun-Yoon Kim, Won Chang, Jeong Min Lee, Se Woo Kim, Jae Seok Bae, Jeongin Yoo, Sun Kyung Jeon, HeeSoo Kim, Young Hoon Kim, Jin-Young Choi, Eun Ju Cho, Yun Bin Lee, Sook-Hyang Jeong, Do Young Kim, Yunhee Choi, Jeong Hee Yoon European Radiology.2025;[Epub] CrossRef
Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure Rui-Min Lai, Li-Xi Yao, Shan Lin, Jia-Hui Zhou, Bing-Ping Liu, Zhao-Yi Liang, Tianbin Chen, Jia-Ji Jiang, Qi Zheng, Yueyong Zhu Expert Review of Gastroenterology & Hepatology.2024; 18(1-3): 103. CrossRef
Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients Yu-Tong Sun, Qian-Qian Chen World Journal of Hepatology.2024; 16(1): 109. CrossRef
Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis Sixing Shen, Lingyan Pan Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B Danny Con, Steven Tu, Daniel Clayton-Chubb, John S. Lubel, Amanda J. Nicoll, Rohit Sawhney, Stephen Bloom Digestive Diseases and Sciences.2024; 69(4): 1496. CrossRef
Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis Shi-Yi Liu, Dian Wang, Jing Liu, Lu-Ping Yang, Gong-Ying Chen World Journal of Hepatology.2024; 16(3): 465. CrossRef
Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences Apichat Kaewdech, Pimsiri Sripongpun Siriraj Medical Journal.2024; 76(4): 234. CrossRef
Nonalcoholic fatty liver disease in Sub-Saharan Africa: A descriptive study of the range of histopathological findings in the South-West zone of Nigeria Olusegun Sylvester Ojo, Olusegun Adekanle, Dennis Ndububa, Olawunmi Kolawole, Omolade Adefolabi Betiku Nigerian Journal of Gastroenterology and Hepatology.2024; 16(1): 42. CrossRef
Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation Jun Wang, Hongzhou Lu, Qian Li Frontiers in Immunology.2024;[Epub] CrossRef
Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis Li Zhang, Hong-Di Wu, Yuan-Fang Qian, Hong-Yan Xu World Journal of Clinical Cases.2024; 12(25): 5749. CrossRef
Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz Heliyon.2024; 10(18): e37990. CrossRef
Revolutionizing the understanding of liver disease: Metabolism, function and future Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez World Journal of Hepatology.2024; 16(12): 1365. CrossRef
Hepatic steatosis: Ultrasound assessment using attenuation imaging (ATI) with liver biopsy correlation Christopher J Welman, Jacqualine Saunders, Marilyn Zelesco, Steven Abbott, Glenn Boardman, Oyekoya T Ayonrinde Journal of Medical Imaging and Radiation Oncology.2023; 67(1): 45. CrossRef
Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection Chang-Hai Liu, Wei Jiang, Dong-Bo Wu, Qing-Min Zeng, You-Juan Wang, Hong Tang Digestive Diseases and Sciences.2023; 68(4): 1605. CrossRef
The interplay of long noncoding RNAs and hepatitis B virus Nima Sarfaraz, Srinivas Somarowthu, Michael J. Bouchard Journal of Medical Virology.2023;[Epub] CrossRef
Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis Xianhua Mao, Ka Shing Cheung, Chengzhi Peng, Lung‐Yi Mak, Ho Ming Cheng, James Fung, Noam Peleg, Howard H.‐W. Leung, Rajneesh Kumar, Jeong‐Hoon Lee, Amir Shlomai, Man‐Fung Yuen, Wai‐Kay Seto Hepatology.2023; 77(5): 1735. CrossRef
Letter: metabolic dysfunction‐associated fatty liver disease increases risk of all‐cause mortality in patients with chronic hepatitis C Qianwen Zhao, Yunlei Deng Alimentary Pharmacology & Therapeutics.2023; 57(2): 272. CrossRef
The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis Cheng-Long Han, Bao-Wen Tian, Chun-Cheng Yang, Ya-Fei Yang, Yun-Long Ma, Zi-Niu Ding, Lun-Jie Yan, Hui Liu, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Dong-Xu Wang, Tao Li Expert Review of Gastroenterology & Hepatology.2023; 17(2): 189. CrossRef
Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao Heliyon.2023; 9(1): e13113. CrossRef
Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection Haifeng Lv, Yanming Jiang, Geli Zhu, Shiyi Liu, Dian Wang, Jie Wang, Ke Zhao, Jing Liu Scientific Reports.2023;[Epub] CrossRef
Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease Pengyan Zhang, Zhenqiu Liu, Hong Fan, Tingting Shi, Xinyu Han, Chen Suo, Xingdong Chen, Tiejun Zhang European Journal of Gastroenterology & Hepatology.2023; 35(3): 294. CrossRef
A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD Jian Wang, Rui Huang, Jiacheng Liu, Ruimin Lai, Yilin Liu, Chuanwu Zhu, Yuanwang Qiu, Zebao He, Shengxia Yin, Yuxin Chen, Xiaomin Yan, Weimao Ding, Qi Zheng, Jie Li, Chao Wu Journal of Viral Hepatitis.2023; 30(4): 287. CrossRef
Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease You-Wen Tan, Jia-Min Wang, Xing-Bei Zhou World Journal of Hepatology.2023; 15(2): 237. CrossRef
Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma Ke-Gong Xiong, Tai-Shun Lin, Jin-Feng Kong, Qing-Biao Lin, Li-Fang Chen, Kun-Yu Ke Medicine.2023; 102(9): e33062. CrossRef
Pyroptosis, Metabolism, and Oxidation in Tumorigenesis: Mechanisms and Therapeutic Implications Qi Cao, Jia-Bao Zhang, Di-Yang Sun, Jiang-Tao Fu, Wen-Bin Wu, Xiao-Fei Chen, Dong-Jie Li, Pei Wang Antioxidants & Redox Signaling.2023; 39(7-9): 512. CrossRef
The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy Yang Wang, Jiaxi Li, Shanshan Wang, Yuheng Pang, Pengxiang Liu, Bangxiang Xie, Shuangshuang Dou, Tongwang Yang, Xiaoni Liu, Ying Shi, Dexi Chen Free Radical Biology and Medicine.2023; 204: 326. CrossRef
Impact of prior HBV, HAV, and HEV infection on non‐alcoholic fatty liver disease Stephanos Vassilopoulos, Markos Kalligeros, Athanasios Vassilopoulos, Fadi Shehadeh, Gregorio Benitez, Matthew Kaczynski, Ingrid Lazaridou, Kittichai Promrat, Jack R. Wands, Eleftherios Mylonakis Journal of Viral Hepatitis.2023; 30(8): 685. CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik JHEP Reports.2023; 5(9): 100810. CrossRef
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vince Clinical and Molecular Hepatology.2023; 29(3): 705. CrossRef
The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis Nor Asiah Muhamad, Nur Hasnah Maamor, Fatin Norhasny Leman, Zuraifah Asrah Mohamad, Sophia Karen Bakon, Mohd Hatta Abdul Mutalip, Izzah Athirah Rosli, Tahir Aris, Nai Ming Lai, Muhammad Radzi Abu Hassan Interactive Journal of Medical Research.2023; 12: e40653. CrossRef
Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients Rui-Min Lai, Shan Lin, Miao-Miao Wang, Na Li, Jia-Hui Zhou, Xiao-Yu Lin, Tian-Bin Chen, Yue-Yong Zhu, Qi Zheng World Journal of Hepatology.2023; 15(8): 964. CrossRef
Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV–HIV Co-infected Adults Richard K. Sterling, Wendy C. King, Mandana Khalili, David E. Kleiner, Amanda S. Hinerman, Mark Sulkowski, Raymond T. Chung, Mamta K. Jain, M auricio Lisker-Melman, David K. Wong, Marc G. Ghany Digestive Diseases and Sciences.2022; 67(2): 676. CrossRef
Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia Madhumita Premkumar, Yogesh K. Chawla Journal of Clinical and Experimental Hepatology.2022; 12(1): 144. CrossRef
Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection Si Ho Kim, Eun Ju Cho, Boo‐ok Jang, Kyunghan Lee, Jae Kyun Choi, Gwang Hyeon Choi, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Yun Bin Lee, Jeong‐Hwan Yoon, Jin‐Wook Kim, Sook‐Hyang Jeong, Eun Sun Jang Liver International.2022; 42(2): 320. CrossRef
Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Sang Hoon Ahn Alimentary Pharmacology & Therapeutics.2022; 55(1): 97. CrossRef
Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC Lei Liu, Si Xie, Yu-Xian Teng, Zhu-Jian Deng, Kang Chen, Hao-Tian Liu, Rong-Rui Huo, Xiu-Mei Liang, Ping-Ping Guo, Da-Long Yang, Liang Ma, Bang-De Xiang, Le-Qun Li, Jian-Hong Zhong Frontiers in Oncology.2022;[Epub] CrossRef
Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America Hin Hin Ko, Nishi H. Patel, Sarah Haylock-Jacobs, Karen Doucette, Mang M. Ma, Curtis Cooper, Erin Kelly, Magdy Elkhashab, Edward Tam, Robert Bailey, Alexander Wong, Gerald Minuk, Philip Wong, Scott K. Fung, Giada Sebastiani, Alnoor Ramji, Carla S. Coffin Gastro Hep Advances.2022; 1(1): 106. CrossRef
MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients Xiaoman Chen, Jing Zhou, Lili Wu, Xiang Zhu, Hong Deng Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 673. CrossRef
Validation for models for tumor recurrence after liver transplantation in hepatectomy patients Sung Joon Kim, Jong Man Kim, Nam-Joon Yi, Gyu-Seong Choi, Kwang-Woong Lee, Kyung-Suk Suh, Jae-Won Joh Annals of Surgical Treatment and Research.2022; 102(3): 131. CrossRef
A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease Xuemei Tao, Lin Chen, Youfei Zhao, Yonggang Liu, Ruifang Shi, Bei Jiang, Yuqiang Mi, Liang Xu Frontiers in Medicine.2022;[Epub] CrossRef
Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients Han Ah Lee, Hyun Woong Lee, Younhee Park, Hyon-Suk Kim, Yeon Seok Seo Journal of Clinical Medicine.2022; 11(6): 1729. CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
Precision medicine in the era of potent antiviral therapy for chronic hepatitis B Eileen L. Yoon, Dae Won Jun Journal of Gastroenterology and Hepatology.2022; 37(7): 1191. CrossRef
Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure Lu Chen, Jinjin Dai, Qing Xie, Xiaolin Wang, Wei Cai Gut and Liver.2022; 16(3): 456. CrossRef
Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia Ming Yang, Lai Wei Liver International.2022; 42(9): 1981. CrossRef
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef
Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim Abdominal Radiology.2022; 47(11): 3733. CrossRef
Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease Xin Tong, Yu Song, Shengxia Yin, Jian Wang, Rui Huang, Chao Wu, Junping Shi, Jie Li Chinese Medical Journal.2022; 135(14): 1653. CrossRef
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen Clinical and Molecular Hepatology.2022; 28(4): 790. CrossRef
Progress in understanding of association between metabolic associated fatty liver disease and viral infectious diseases Zhao-Chun Chi World Chinese Journal of Digestology.2022; 30(18): 783. CrossRef
Interaction and Possible Mechanism between Non-Alcoholic Fatty Liver Disease and Chronic Hepatitis B 博诗 陈 Advances in Clinical Medicine.2022; 12(11): 10453. CrossRef
Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee Journal of Korean Medical Science.2022;[Epub] CrossRef
Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease Changtian Su, Qin Yang Frontiers in Pharmacology.2022;[Epub] CrossRef
NAFLD and HBV interplay - related mechanisms underlying liver disease progression Evanthia Tourkochristou, Stelios F. Assimakopoulos, Konstantinos Thomopoulos, Markos Marangos, Christos Triantos Frontiers in Immunology.2022;[Epub] CrossRef
Metabolic syndromes, hepatitis B virus (HBV), and hepatitis C virus as three factors involved in the development of hepatic steatosis: a systematic review and meta-analysis Masoud Keikha, Amirhossein Sahebkar, Tannaz Jamialahmadi, Mohsen Karbalaei Reviews and Research in Medical Microbiology.2022; 33(3): 139. CrossRef
Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies Jonggi Choi, Young‐Suk Lim The Kaohsiung Journal of Medical Sciences.2021; 37(4): 262. CrossRef
HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging Ai-Mei Li, Xia-Wen Lin, Jing-Tao Shen, Min Li, Qi-Huang Zheng, Zheng-Yang Zhou, Ming Shi Nuclear Medicine and Biology.2021; 96-97: 27. CrossRef
The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B Minah Kim, Yeonju Lee, Jun Sik Yoon, Minjong Lee, So Shin Kye, Sun Woong Kim, Yuri Cho Cancers.2021; 13(10): 2301. CrossRef
Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B Yun Bin Lee, Hyemi Moon, Jeong‐Hoon Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Fabien Zoulim, Juneyoung Lee, Jung‐Hwan Yoon Hepatology.2021; 73(6): 2266. CrossRef
Pyroptosis: mechanisms and diseases Pian Yu, Xu Zhang, Nian Liu, Ling Tang, Cong Peng, Xiang Chen Signal Transduction and Targeted Therapy.2021;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B Laurens A. van Kleef, Hannah S.J. Choi, Willem P. Brouwer, Bettina E. Hansen, Keyur Patel, Robert A. de Man, Harry L.A. Janssen, Robert J. de Knegt, Milan J. Sonneveld JHEP Reports.2021; 3(5): 100350. CrossRef
Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B Qi Zheng, Biyao Zou, Yuankai Wu, Yeehui Yeo, Huizhen Wu, Christopher D Stave, Ramsey C. Cheung, Mindie H. Nguyen Alimentary Pharmacology & Therapeutics.2021; 54(9): 1100. CrossRef
Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy Rong Fan, Junqi Niu, Hong Ma, Qing Xie, Jun Cheng, Huiying Rao, Xiaoguang Dou, Jianping Xie, Wei Zhao, Jie Peng, Zhiliang Gao, Hongbo Gao, Xinyue Chen, Jinjun Chen, Qiang Li, Hong Tang, Zhengang Zhang, Hong Ren, Mingliang Cheng, Xieer Liang, Chaonan Zhu, Alimentary Pharmacology & Therapeutics.2021; 54(3): 329. CrossRef
Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy Joo Hyun Oh, Hye Won Lee, Dong Hyun Sinn, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Wonseok Kang, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik Hepatology International.2021; 15(4): 892. CrossRef
Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion Yi-Wen Shi, Rui-Xu Yang, Jian-Gao Fan World Journal of Gastroenterology.2021; 27(26): 3971. CrossRef
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Hepatocellular Carcinoma.2021; Volume 8: 467. CrossRef
REPLY: Yun Bin Lee, Juneyoung Lee Hepatology.2021; 74(2): 1135. CrossRef
Reply Hye Won Lee, Beom Kyung Kim Clinical Gastroenterology and Hepatology.2020; 18(1): 264. CrossRef
Magnetic resonance imaging of obesity and metabolic disorders: Summary from the 2019 ISMRM Workshop Houchun H. Hu, Rosa Tamara Branca, Diego Hernando, Dimitrios C. Karampinos, Jürgen Machann, Charles A. McKenzie, Holden H. Wu, Takeshi Yokoo, S. Sendhil Velan Magnetic Resonance in Medicine.2020; 83(5): 1565. CrossRef
Abnormal CD44 activation of hepatocytes with nonalcoholic fatty accumulation in rat hepatocarcinogenesis Miao Fang, Min Yao, Jie Yang, Wen-Jie Zheng, Li Wang, Deng-Fu Yao World Journal of Gastrointestinal Oncology.2020; 12(1): 66. CrossRef
Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors? Jianbin Zhang, Shuangzhe Lin, Daixi Jiang, Mengting Li, Yuanwen Chen, Jun Li, Jiangao Fan Liver International.2020; 40(3): 496. CrossRef
Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Jonggi Choi, Gi-Ae Kim, Seungbong Han, Young-Suk Lim American Journal of Gastroenterology.2020; 115(3): 406. CrossRef
Approach to the patient with chronic hepatitis B and decompensated cirrhosis Mitchell L. Shiffman Liver International.2020; 40(S1): 22. CrossRef
Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up Chong Teik Lim, George Boon Bee Goh, Huihua Li, Tony Kiat-Hon Lim, Wei Qiang Leow, Wei Keat Wan, Rafay Azhar, Wan Cheng Chow, Rajneesh Kumar Microbiology Insights.2020;[Epub] CrossRef
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B Han Ah Lee, Yeon Seok Seo, Seung Up Kim Gastroenterology.2020; 158(8): 2310. CrossRef
Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B Hyeki Cho, Young Chang, Jeong-Hoon Lee, Young Youn Cho, Joon Yeul Nam, Yun Bin Lee, Dong Ho Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jeong Min Lee, Jung-Hwan Yoon Journal of Clinical Gastroenterology.2020; 54(7): 633. CrossRef
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau, Aysha Aslam Microorganisms.2020; 8(10): 1526. CrossRef
Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune‐tolerant phase—authors' reply Han Ah Lee, Seung Up Kim Alimentary Pharmacology & Therapeutics.2020; 52(6): 1094. CrossRef
The Effects of Hepatic Steatosis on the Natural History of HBV Infection Idrees Suliman, Noha Abdelgelil, Farah Kassamali, Tarek I. Hassanein Clinics in Liver Disease.2019; 23(3): 433. CrossRef
First
Prev
